METHYLTESTOSTERONE


Trade Names	ANDROID 10 ANDROID 25 ANDROID 5 METANDREN METHYLTESTOSTERONE ORETON ORETON METHYL TESTRED VIRILON
Synonyms	17-methyltestosterone Android 10 Android 25 Android 5 CDB-110 L 589.372 L-589.372 L-589372 Metandren Methitest Methyltestosterone Methyltestosterone ciii NSC-139965 NSC-9701 Oreton
Status
Molecule Category	Free-form
ATC	G03BA02 G03EK01
UNII	V9EFU16ZIF
EPA CompTox	DTXSID1033664

Structure


InChI Key	GCKMFJBGXUYNAG-HLXURNFRSA-N
Smiles	C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
InChI	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H30O2
Molecular Weight	302.46
AlogP	4.27
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Polar Surface Area	37.3
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	22.0

Pharmacology

Mechanism of Action	Action	Reference
Androgen Receptor agonist	AGONIST	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Secreted protein	-	-	3.715	-	-
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 4	-	15.85	-	-	-

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Homo sapiens	-	-	3.715	-	-
Rattus norvegicus	-	15.85	-	-	-

Target Conservation


Protein: Androgen Receptor Description: Androgen receptor Organism : Homo sapiens P10275 ENSG00000169083

Related Entries

Cross References

Resources	Reference
ChEBI	27436
ChEMBL	CHEMBL1395
DrugBank	DB06710
DrugCentral	3356
FDA SRS	V9EFU16ZIF
Human Metabolome Database	HMDB0015655
Guide to Pharmacology	6945
KEGG	C07198
PubChem	6010
SureChEMBL	SCHEMBL18657
ZINC	ZINC000003814422

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).